- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2020 State of the States Medical Cannabis Access for Pain Treatment Medical Cannabis in America
- Join Join
This blog was originally published 10/31/13.
Cannabis and its derivatives have been documented for anti-epileptic effects since 1881. Today, the promise of cannabidiol (CBD) as an anti-epileptic treatment is prompting people to move to states that have safe access to medicinal products containing this compound. There are increasing reports of CBD being used by parents to treat seizure disorders in their children. This use of a cannabinoid to treat seizures is not unfounded, the ever-popular THC molecule has been studied in children with seizure disorders. The results of early cannabinoid clinical studies and anecdotal findings for epilepsy are promising.
CBD is becoming more popular than THC, because CBD appears to provide relief and does not cause a “high”, and acts on receptors that differ from those of THC. The FDA has approved a new clinical study with CBD, but it is unclear how this drug works. A molecular mechanism that completely explains the effects of CBD has not yet emerged (But as one doctor said at a recent meeting at NYU “Doctors don't treat molecular mechanisms, they treat people”).
There are two theories that seem plausible to explain CBD’s effects. Or at least these will partially explain how CBD may be acting in the body. One theory supports a role for CBD in the hippocampus. The hippocampus is a hub in the brain for the exchange of information, and epilepsy can occur when this exchange is disrupted. The other theory involves the protective effect of cannabinoids, through proteins known as NMDA receptors. NMDA receptors play a major role in memory and learning, cannabinoids may have a distinct or ‘special’ site of interaction on these receptors too (Gloss & Vickrey 2012).
It may be hard to believe, but clinical studies with CBD have been going on since 1978. However, there are only a handful of studies that examined CBD alone in the last 30 years. A preparation of CBD in combination with THC has been the subject of numerous clinical trials, known as the drug Sativex. There have been some recent anecdotal reports of CBD that were published in the scientific literature and on CNN.
An early anecdotal report with 5 institutionalized children being treated with THC for epilepsy resulted in: one seizure free kid, one almost seizure free kid, and 3 that experienced no significant change (Davis and Ramsey, 1949).
A CBD clinical study published in 1980 resulted in: “4 of the 8 CBD subjects remained almost free of convulsive crises throughout the experiment and 3 other patients demonstrated partial improvement in their clinical condition. CBD was ineffective in 1 patient. The clinical condition of 7 placebo patients remained unchanged whereas the condition of 1 patient clearly improved.”
There is a fair amount of information known about the potential therapeutic benefits of CBD from limited clinical studies, anecdotal information from both hospitals and parents, as well as a wealth of animal data. It is safe to say there is more than enough evidence to support large-scale clinical trials with CBD, it is non-toxic and generally well tolerated in clinical studies and anecdotal reports. However, the number of patients given pure CBD is small, and the studies are generally short in duration and this prevents mainstream medicine from drawing any reliable conclusions about the efficacy of cannabinoids for epilepsy. Bringing CBD into rigorous clinical trials will provide medical professionals with the information to prescribed CBD based medicines.
Here are a few links to full scientific articles that will provide an overview and a lot of background information on cannabinoids for epilepsy:
- Cannabidiol Displays Antiepileptiform and Antiseizure Properties In Vitro and In Vivo
- Exogenous and Endogenous Cannabinoids Suppress Inhibitory Neurotransmission in the Human Neocortex
- Endocannabinoid system protects against cryptogenic seizures
- Commentary-Slim Evidence for Cannabinoids for Epilepsy
- Neuron to astrocyte communication via cannabinoid receptors is necessary for sustained epileptiform activity in rat hippocampus